Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | F2R | P25116 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.42 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3565281 | 1.00 | MEN1 (0.48) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL3570355 | 0.86 | KMT2A (0.50) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL3570354 | 0.86 | KMT2A (0.50) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL6016645 | 0.85 | MEN1 (0.57) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL6016643 | 0.85 | MEN1 (0.57) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL12108846 | 0.84 | MEN1 (0.49) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL2953731 | 0.83 | CYP11B1 (0.50) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL2953727 | 0.83 | CYP11B1 (0.50) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL29398562 | 0.83 | CYP11B1 (0.50) | MEN1KMT2AMAPTLMNANPSR1 | |
| SCHEMBL955148 | 0.83 | CYP11B1 (0.52) | MEN1KMT2AMAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825278-B2 | Substituted enaminones, their derivatives and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080064748-A1 | Substituted enaminones, their derivatives and uses thereof | OXFORD FINANCE CORPORATION | 2008-03-13 | — | — | US | disclosed |
| EP-1742904-A4 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | UNIV CALIFORNIA (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1742904-A2 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1187815-B1 | 4-PHENYL-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005108347-A2 | SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-11-17 | — | — | WO | disclosed |
| EP-1187815-A1 | 4-PHENYL-PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-20 | — | — | EP | disclosed |
| US-6274588-B1 | NEUROKININ OR SUBSTANCE P ANTAGONISTS; CENTRAL NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDES; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | HOFFMANN-LA ROCHE INC. | 2001-08-14 | — | — | US | disclosed |
| WO-2000073279-A1 | 4-PHENYL-PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064748-A1 | Substituted enaminones, their derivatives and uses thereof | GABRB2, GABRB1, GABRB3 | MEN1 2446/4885KMT2A 3043/4885MAPT 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.